Background: A new Chinese medicinal compound including Isatdis Radix, Forsythiae Fructus, Mori Cortex, Ginkgo Folium, Licorice and Radix Salviae was pre-screened through the method of network pharmacology for the treatment of co-infection of Mycoplasma gallisepticum and Escherichia Coli. While, the optimal combination of Chinese medicine is still an obstacle to the development of the Chinese medicinal compound.Results: A multi-indicators evaluation method was used in this study to establish a comprehensive assessment system based on the minimal inhibitory concentration of Mycoplasma gallisepticum and Escherichia Coli in vitro, air sac and tracheal lesion scores in vivo. We used the min-max normalization method to normalize the scores of the four metrics and gave them the same proportion of weights to calculate the total score. Then, according to the method of uniform test, the six-factor ten-level experiment (U*10(106) was designed, with the total score as the index. The multi-nonlinear regression equation was established by data processing system according to the comprehensive index. The results showed that the ratio of Isatdis Radix, Forsythiae Fructus, Ginkgo Folium, Mori Cortex, Licorice and Radix Salviae were 14:7:11:12:5:3, which showed effective treatment. Conclusions: It turned out that uniform design can be effectively used to solve dose optimization for combined use of multiple compounds. In addition, this study also proposes a new method to comprehensively evaluate medicinal compounds for respiratory diseases such as Mycoplasma gallisepticum and Escherichia Coli infection.